File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Protective effects of desacyl ghrelin on diabetic cardiomyopathy

TitleProtective effects of desacyl ghrelin on diabetic cardiomyopathy
Authors
KeywordsType 2 diabetes mellitus
Ghrelin
Fibrosis
Cardiomyopathy
Autophagy
Issue Date2015
Citation
Acta Diabetologica, 2015, v. 52, n. 2, p. 293-306 How to Cite?
Abstract© 2014, Springer-Verlag Italia. Aim: Diabetic cardiomyopathy is a specific complication of type 2 diabetes mellitus, which causes progressive cardiac dysfunction. Desacyl ghrelin has been preliminarily demonstrated to have beneficial effects on cardiovascular system and glucose metabolism, which are both related to diabetic cardiomyopathy. The aim of this study was to investigate the protective effects of desacyl ghrelin on cardiac dysfunction, cardiac fibrosis, and cellular autophagy in a type 2 diabetic mouse model. Materials and methods: Fourteen- to eighteen-week-old db/db diabetic and db/+ non-diabetic mice were intraperitoneally treated with desacyl ghrelin at a dosage of 100 μg/kg for ten consecutive days. Ventricular fractional shortening was examined as an indicator of cardiac function by transthoracic echocardiography. Results: The presence of diabetic cardiomyopathy was evident by the reduction in fractional shortening shown in our examined db/db mice. Intriguingly, this reduction in fractional shortening was not observed in the hearts of db/db mice treated with desacyl ghrelin. Cardiac fibrosis (indicated by excessive collagen deposition, decreased by Adiponectin and Mmp13 expression, and up-regulated by Mmp8 expression) and impairment of autophagic signalling (indicated by decreases in Foxo3 and LC3 II-to-LC3 I ratio) were shown in the hearts of diabetic mice. All these cellular and molecular alterations were alleviated by desacyl ghrelin treatment. The key cardiac pro-survival cellular signals including AMPK, Akt, ERK1/2, and GSK3α/β were impaired in the diabetic hearts, but the administration of desacyl ghrelin attenuated these signalling impairments. Conclusions: These results collectively demonstrate that desacyl ghrelin protects the heart against cardiac dysfunction in type 2 diabetic mice by inhibiting excessive collagen deposition and enhancing cardiac autophagic signalling via the pro-survival cellular AMPK/ERK1/2 signalling pathways.
Persistent Identifierhttp://hdl.handle.net/10722/244187
ISSN
2022 Impact Factor: 3.8
2020 SCImago Journal Rankings: 1.141
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPei, Xiao M.-
dc.contributor.authorYung, Benjamin Y.-
dc.contributor.authorYip, Shea P.-
dc.contributor.authorChan, Lawrence W.-
dc.contributor.authorWong, Cesar S.-
dc.contributor.authorYing, Michael-
dc.contributor.authorSiu, Parco M.-
dc.date.accessioned2017-08-31T08:56:17Z-
dc.date.available2017-08-31T08:56:17Z-
dc.date.issued2015-
dc.identifier.citationActa Diabetologica, 2015, v. 52, n. 2, p. 293-306-
dc.identifier.issn0940-5429-
dc.identifier.urihttp://hdl.handle.net/10722/244187-
dc.description.abstract© 2014, Springer-Verlag Italia. Aim: Diabetic cardiomyopathy is a specific complication of type 2 diabetes mellitus, which causes progressive cardiac dysfunction. Desacyl ghrelin has been preliminarily demonstrated to have beneficial effects on cardiovascular system and glucose metabolism, which are both related to diabetic cardiomyopathy. The aim of this study was to investigate the protective effects of desacyl ghrelin on cardiac dysfunction, cardiac fibrosis, and cellular autophagy in a type 2 diabetic mouse model. Materials and methods: Fourteen- to eighteen-week-old db/db diabetic and db/+ non-diabetic mice were intraperitoneally treated with desacyl ghrelin at a dosage of 100 μg/kg for ten consecutive days. Ventricular fractional shortening was examined as an indicator of cardiac function by transthoracic echocardiography. Results: The presence of diabetic cardiomyopathy was evident by the reduction in fractional shortening shown in our examined db/db mice. Intriguingly, this reduction in fractional shortening was not observed in the hearts of db/db mice treated with desacyl ghrelin. Cardiac fibrosis (indicated by excessive collagen deposition, decreased by Adiponectin and Mmp13 expression, and up-regulated by Mmp8 expression) and impairment of autophagic signalling (indicated by decreases in Foxo3 and LC3 II-to-LC3 I ratio) were shown in the hearts of diabetic mice. All these cellular and molecular alterations were alleviated by desacyl ghrelin treatment. The key cardiac pro-survival cellular signals including AMPK, Akt, ERK1/2, and GSK3α/β were impaired in the diabetic hearts, but the administration of desacyl ghrelin attenuated these signalling impairments. Conclusions: These results collectively demonstrate that desacyl ghrelin protects the heart against cardiac dysfunction in type 2 diabetic mice by inhibiting excessive collagen deposition and enhancing cardiac autophagic signalling via the pro-survival cellular AMPK/ERK1/2 signalling pathways.-
dc.languageeng-
dc.relation.ispartofActa Diabetologica-
dc.subjectType 2 diabetes mellitus-
dc.subjectGhrelin-
dc.subjectFibrosis-
dc.subjectCardiomyopathy-
dc.subjectAutophagy-
dc.titleProtective effects of desacyl ghrelin on diabetic cardiomyopathy-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00592-014-0637-4-
dc.identifier.pmid25192951-
dc.identifier.scopuseid_2-s2.0-84924297804-
dc.identifier.volume52-
dc.identifier.issue2-
dc.identifier.spage293-
dc.identifier.epage306-
dc.identifier.eissn1432-5233-
dc.identifier.isiWOS:000351835500009-
dc.identifier.issnl0940-5429-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats